Clinical Policy: Temozolomide (Temodar)
Reference Number: CP.PHAR.77
Effective Date: 09.01.11
Last Review Date: 05.19
Line of Business: HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Temozolomide (Temodar®) is an imidazotetrazine derivative.

FDA Approved Indication(s)
Temodar is indicated for the treatment of:
- Adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment
- Adult patients with refractory anaplastic astrocytoma, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Temodar is medically necessary when the following criteria are met:

I. Initial Approval Criteria
A. Glioblastoma (must meet all):
   1. Diagnosis of glioblastoma*;
   2. Prescribed by or in consultation with an oncologist;
   3. Age ≥ 18 years;
   4. Request meets one of the following (a or b):
      a. Dose does not exceed 200 mg/m²/day;
      b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 6 months

* A high-grade WHO grade IV glioma also known as glioblastoma multiforme (GBM).

B. Anaplastic Astrocytoma (must meet all):
   1. Diagnosis of anaplastic astrocytoma*;
   2. Prescribed by or in consultation with an oncologist;
   3. Age ≥ 18 years;
   4. Request meets one of the following (a or b):
      a. Dose does not exceed 200 mg/m²/day;
b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 6 months

*A high-grade WHO grade III glioma.

C. NCCN Compendium Supported Uses (off-label) (must meet all):
1. Prescribed for one of the following NCCN category 1 or 2a recommended indications:
   a. Ewing sarcoma in combination with irinotecan for relapsed or progressive disease
   b. Adult intracranial and spinal ependymoma as a single-agent for disease progression
   c. Adult medulloblastoma as a single-agent for recurrence in patients who received prior chemotherapy;
   d. Primary CNS lymphoma;
   e. Melanoma as second-line therapy for metastatic or unresectable disease, or after disease progression or maximum clinical benefit from BRAF targeted therapy;
   f. Neuroendocrine tumors of the gastrointestinal tract, pancreas, or pheochromocytoma/paraganglioma
   g. Small cell lung cancer in primary progressive disease or with relapse within 6 months following complete or partial response or stable disease with initial treatment;
   h. Soft tissue sarcoma as palliative treatment for retroperitoneal/intra-abdominal disease, angiosarcoma, and rhabdomyosarcoma;
   i. Soft tissue sarcoma for nonpleomorphic rhabdomyosarcoma in combination with vincristine and irinotecan;
   j. Soft tissue sarcoma for solitary fibrous tumor and hemangiopericytoma in combination with bevacizumab;
   k. Mycosis fungoides/Sézary syndrome;
   l. Uterine sarcoma;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request meets one of the following (a or b):
   a. Dose does not exceed 200 mg/m²/day;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration: 6 months

D. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.
II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that
         member is currently receiving Temodar and has received this medication for at least
         30 days;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, request meets one of the following (a or b):
         a. New dose does not exceed 200 mg/m²/day;
         b. New dose is supported by practice guidelines or peer-reviewed literature for the
            relevant off-label use (prescriber must submit supporting evidence).

   Approval duration: 12 months

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports
         positive response to therapy.

         Approval duration: Duration of request or 6 months (whichever is less); or

      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
         specifically listed under section III (Diagnoses/Indications for which coverage is
         NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53
         for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is
      sufficient documentation of efficacy and safety according to the off label use policies –
      HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or
      evidence of coverage documents.

IV. Appendices/General Information

   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration
   CNS: central nervous system
   NCCN: National Comprehensive Cancer Network
   WHO: World Health Organization

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval
   criteria. The drugs listed here may not be a formulary agent for all relevant lines of business
   and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin® (bevacizumab)</td>
<td>Glioblastoma and Anaplastic Astrocytoma</td>
<td>Varies</td>
</tr>
<tr>
<td></td>
<td>Varies upon protocol and patient tolerance</td>
<td></td>
</tr>
<tr>
<td>Nitrosoureas* (e.g., carmustine, fotemustine, lomustine)</td>
<td>Anaplastic Astrocytoma</td>
<td>Varies</td>
</tr>
<tr>
<td></td>
<td>Varies upon protocol and patient tolerance</td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/ Maximum Dose</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Procarbazine hydrochloride*</td>
<td>Anaplastic Astrocytoma Varies upon protocol and patient tolerance</td>
<td>Varies</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Example of a regimen containing a nitrosourea and procarbazine: PCV (procarbazine, lomustine, vincristine).

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Glioblastoma multiforme           | **Concomitant phase:** 75 mg/m2 daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions) followed by maintenance Temodar for 6 cycles. **Maintenance phase:**  
  • **Cycle 1:** Four weeks after completing the Temodar+RT phase, Temodar is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m² once daily for 5 days followed by 23 days without treatment. **Cycles 2-6:** At the start of Cycle 2, the dose can be escalated to 200 mg/m². The dose remains at 200 mg/m² per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. | 200 mg/m²/day |
| Anaplastic astrocytoma            | Initial dose is 150 mg/m² once daily for 5 consecutive days per 28-day treatment cycle. | 200 mg/m²/day |
VI. Product Availability
- Intravenous reconstituted solution (Temodar): 100 mg
- Oral capsules (Temodar, generic): 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg

VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J8700</td>
<td>Temozolomide, oral, 5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J9328</td>
<td>Injection, temozolomide, 1 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Added efficacy and safety data for Temodar</td>
<td>08.14</td>
<td>08.14</td>
</tr>
<tr>
<td>Added Appendices A, B, C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Algorithm: added initial criteria for Temodar for GBM, pneumocystitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pneumonia question, and approval period for 42 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Algorithm: split original algorithm into two separate figures (GBM and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaplastic astrocytoma), and added 6 cycles to approval period of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temozolomide in GBM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed efficacy and related reference from background.</td>
<td>08.15</td>
<td>08.15</td>
</tr>
<tr>
<td>Updated safety section and added related questions to both algorithms.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendix A: abbreviations maintained</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendices B and C: criteria for initiation and criteria for dosing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>respectively are edited to Appendix B: when to initiate Temozolomide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapy, and Appendix C: when to discontinue Temozolomide therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Policy converted to new template. CBC, LFT, HBV screening requirements</td>
<td>07.16</td>
<td>08.16</td>
</tr>
<tr>
<td>removed. Evidence of HBV infection removed as reason to discontinue;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>remaining reasons to discontinue are separated per indication.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
<td>P&amp;T Approval Date</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------</td>
<td>------------------</td>
</tr>
<tr>
<td>Glioblastoma: Toxicity criteria is restricted to continuation of therapy – footnote added defining Grades 3 and 4. Approved number of FDA labeled adjuvant cycles (after Temodar/radiotherapy) is increased from 6 to 12 cycles total. “No disease progression” is added under continuation criteria. All NCCN compendial uses added; NCCN glioblastoma and anaplastic astrocytoma criteria are outlined in section I. Initial policy approval periods are increased to 6 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glioblastoma adjuvant treatment for 12 cycles post radiotherapy is decreased to 6 cycles. Maximum dose added for both indications. Off-label coverage is limited to NCCN uses categorized as 1 or 2a (2b is removed). For anaplastic astrocytoma: Off-label use as a single agent is limited to positive identification of 1p19q uni- or non-deleted tumor status. Safety information is removed. Renewal periods are increased from 6 to 12 months. HCPCS codes updated</td>
<td>07.17</td>
<td>08.17</td>
</tr>
<tr>
<td>Typo fixed to allow coverage for anaplastic astrocytoma to match FDA approved indication for the treatment of disease that has progressed on a drug regimen containing nitrosourea or procarbazine. Previous policy indicated indicated use in disease that has progressed on nitrosourea and procarbazine</td>
<td>12.17</td>
<td></td>
</tr>
<tr>
<td>2Q 2018 annual review: added HIM line of business; added age; added continuity of care language; summarized NCCN and FDA approved uses for improved clarity; added specialist involvement in care; updated NCCN Compendium supported uses; references reviewed and updated.</td>
<td>02.08.18</td>
<td>05.18</td>
</tr>
<tr>
<td>2Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>02.05.19</td>
<td>05.19</td>
</tr>
</tbody>
</table>

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,